Matthew Ho

2.3k total citations · 1 hit paper
39 papers, 1.5k citations indexed

About

Matthew Ho is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Matthew Ho has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 20 papers in Hematology and 11 papers in Oncology. Recurrent topics in Matthew Ho's work include Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (17 papers) and Ubiquitin and proteasome pathways (7 papers). Matthew Ho is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (17 papers) and Ubiquitin and proteasome pathways (7 papers). Matthew Ho collaborates with scholars based in United States, Ireland and China. Matthew Ho's co-authors include Matthew B. Plutschack, Nils Frank, Florian Berger, Tobias Ritter, Wanwan Yu, Amanda McCann, Giada Bianchi, Luke Gubbins, Karolina Weiner‐Gorzel and Kenneth C. Anderson and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Matthew Ho

36 papers receiving 1.5k citations

Hit Papers

Site-selective and versatile aromatic C−H functionalizati... 2019 2026 2021 2023 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Site-selective and versatile aromatic C−H functionalization by thianthrenation
    2019 569 citations Matthew Ho et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew Ho United States 14 643 541 322 210 206 39 1.5k
Xudong Wei China 20 528 0.8× 501 0.9× 229 0.7× 181 0.9× 79 0.4× 120 1.4k
Kevin W. Kuntz United States 21 2.0k 3.1× 787 1.5× 263 0.8× 155 0.7× 117 0.6× 34 2.7k
Sara M. Schmitt United States 14 1.0k 1.6× 451 0.8× 834 2.6× 168 0.8× 187 0.9× 20 1.9k
M. V. Ramana Reddy United States 23 933 1.5× 733 1.4× 488 1.5× 109 0.5× 305 1.5× 80 2.1k
Xin Han China 24 1.5k 2.4× 536 1.0× 612 1.9× 89 0.4× 371 1.8× 48 2.2k
Michael Frezza United States 14 847 1.3× 640 1.2× 1.0k 3.1× 119 0.6× 154 0.7× 15 1.9k
Susan M. Ludeman United States 20 593 0.9× 193 0.4× 387 1.2× 264 1.3× 162 0.8× 51 1.4k
Neelu Kaila United States 23 586 0.9× 594 1.1× 121 0.4× 85 0.4× 159 0.8× 49 1.3k
Jinfeng Luo China 24 626 1.0× 421 0.8× 335 1.0× 53 0.3× 151 0.7× 55 1.4k
Susan Ashton United Kingdom 14 580 0.9× 236 0.4× 521 1.6× 161 0.8× 52 0.3× 25 1.2k

Countries citing papers authored by Matthew Ho

Since Specialization
Citations

This map shows the geographic impact of Matthew Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Ho more than expected).

Fields of papers citing papers by Matthew Ho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Ho. The network helps show where Matthew Ho may publish in the future.

Co-authorship network of co-authors of Matthew Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Ho. A scholar is included among the top collaborators of Matthew Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Ho. Matthew Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Robert, et al.. (2025). Surgical Management of the Discoid Lateral Meniscus: a Systematic Review of Outcomes. Current Reviews in Musculoskeletal Medicine. 18(11). 513–535.
2.
Ho, Matthew, et al.. (2025). Extramedullary Multiple Myeloma: Challenges and Opportunities. Current Oncology. 32(3). 182–182. 1 indexed citations
3.
Ho, Matthew, Surendra Dasari, Alissa Visram, et al.. (2023). An atlas of the bone marrow bone proteome in patients with dysproteinemias. Blood Cancer Journal. 13(1). 63–63. 4 indexed citations
4.
Ho, Matthew, et al.. (2022). Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Current Oncology. 29(11). 8975–9005. 13 indexed citations
5.
Bianchi, Giada, Peter G. Czarnecki, Matthew Ho, et al.. (2021). ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discovery. 2(4). 338–353. 12 indexed citations
6.
Ho, Matthew, Saurabh Zanwar, Prashant Kapoor, et al.. (2021). The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal. 11(9). 158–158. 6 indexed citations
7.
Robinson, Joshua, et al.. (2021). Synthesis of agelastatin A and derivatives premised on a hidden symmetry element leading to analogs displaying anticancer activity. Tetrahedron. 94. 132340–132340. 4 indexed citations
8.
Ho, Matthew, et al.. (2021). Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resistance. 4. 1028–1046. 9 indexed citations
9.
10.
Ho, Matthew, et al.. (2020). Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma Myeloma & Leukemia. 20(10). e752–e768. 28 indexed citations
11.
Yu, Tengteng, Yan Xu, Gang An, et al.. (2020). Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clinical Lymphoma Myeloma & Leukemia. 20(10). e652–e659. 10 indexed citations
12.
Wyse, Cathy, Matthew Ho, Jane Howard, et al.. (2020). Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?. Cancer Letters. 473. 90–97. 52 indexed citations
13.
Liu, Jiye, Tianyu Song, Lijie Xing, et al.. (2018). A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 33(1). 171–180. 65 indexed citations
14.
Zhang, Yongli, Matthew Ho, Huiqin Zhuo, et al.. (2017). Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis. Acta Haematologica. 137(2). 106–112. 10 indexed citations
15.
Ho, Matthew. (2017). Targeting Protein Synthesis and Degradation in Multiple Myeloma: A Look at What’s on the Horizon. 13(3). 4 indexed citations
16.
Ho, Matthew, Jiye Liu, Alireza Kalbasi, et al.. (2017). Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function. Blood. 130. 4429–4429. 2 indexed citations
17.
Ho, Matthew, Amanda McCann, Giada Bianchi, et al.. (2017). Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leukemia & lymphoma. 59(3). 542–561. 29 indexed citations
18.
Zhang, Li, Yu‐Tzu Tai, Matthew Ho, Lugui Qiu, & Kenneth C. Anderson. (2017). Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era. Experimental Hematology and Oncology. 6(1). 20–20. 29 indexed citations
19.
20.
Gubbins, Luke, Shiva Sharma, Riona Tully, et al.. (2015). The fate of chemoresistance in triple negative breast cancer (TNBC). PubMed. 3. 257–275. 306 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xudong Wei Breakdown of academic impact, for papers by Kevin W. Kuntz Breakdown of academic impact, for papers by Sara M. Schmitt Breakdown of academic impact, for papers by M. V. Ramana Reddy Breakdown of academic impact, for papers by Xin Han Breakdown of academic impact, for papers by Michael Frezza Breakdown of academic impact, for papers by Susan M. Ludeman Breakdown of academic impact, for papers by Neelu Kaila Breakdown of academic impact, for papers by Jinfeng Luo Breakdown of academic impact, for papers by Susan Ashton
Rankless by CCL
2026